{
  "slug": "childhood-cancer-diagnosis",
  "question": "What are the odds of a child being diagnosed with cancer before age 20?",
  "quick_answer": "Roughly 1 in 285 children are diagnosed with cancer before age 20. That is far below the 1-in-20-to-1-in-5 range most parents guess — the outcome's severity makes even a small probability feel much larger.\n",
  "category": "health",
  "tags": [
    "kids",
    "child"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Parents consistently rank childhood cancer among their greatest fears, and the perceived probability sits well above the actual rate. The vividness and emotional weight of childhood cancer diagnoses in media coverage — charity drives, viral fundraising stories, celebrity disclosures — create an availability cascade that inflates intuitive estimates dramatically. When researchers ask parents to estimate the likelihood that their child will develop cancer before adulthood, the guesses routinely fall between 5% and 20%, far above the actual cumulative incidence of roughly 1 in 285. The gap is amplified by the severity of the outcome: even a very small probability feels large when the outcome is cancer in a child.\n",
    "rough_estimate": "Most parents would guess somewhere between 1 in 20 and 1 in 5 — roughly 14 to 57 times the actual rate",
    "kind": "intuition"
  },
  "native": {
    "display": "roughly 216 children diagnosed with cancer per 1,000,000 children per year (US, ages 0–19)",
    "numerator": 216,
    "denominator": 1000000,
    "unit": "per child per year (ages 0–19)",
    "population": "US children aged 0–19"
  },
  "normalized": {
    "lifetime_us_adult": 0.00351,
    "display": "roughly 1 in 285 children diagnosed with cancer before age 20 (US)",
    "log_value": -2.45,
    "assumptions": "NCI SEER data (2023 Cancer Statistics Review, Childhood Cancer Statistics table) reports approximately 15,780 new cancer cases per year among US children aged 0–19 (average 2016–2020). The US Census Bureau estimated approximately 73 million children under age 20 in that period. Annual incidence rate: 15,780 / 73,000,000 ≈ 216 per million (21.6 per 100,000) per year. Cumulative childhood probability (20 independent annual-trial approximation): P = 1 − (1 − 0.000216)^20 ≈ 0.00430. However, NCI's own published summary statistic \"approximately 1 in 285 children will be diagnosed with cancer before age 20\" is the authoritative figure (0.003509) — it incorporates age-specific rate variation more precisely than the simple constant-rate approximation. This entry uses 0.00351 as the point estimate, consistent with the NCI published summary. Scope: subgroup_lifetime — probability that a given child receives a cancer diagnosis during their 0–19 childhood, not a US adult's remaining lifetime probability.\n",
    "uncertainty": {
      "low": 0.003,
      "high": 0.004
    },
    "scope": "subgroup_lifetime"
  },
  "sources": [
    {
      "url": "https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet",
      "title": "Cancer in Children and Adolescents — NCI Fact Sheet",
      "publisher": "National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program",
      "source_type": "govt_report",
      "statistic": "An estimated 14,910 children and adolescents aged 0–19 will be diagnosed with cancer in the US in 2024; 5-year relative survival ~83–88% across childhood age bands (2013–2019)",
      "excerpt": "\"It is estimated that, in 2024, a total of 14,910 children and adolescents ages 0 to 19 will be diagnosed with cancer... In 2013–2019, 5-year survival was 83.2% for children younger than 1 year, 87.8% for children ages 1–4 years, 85.7% for children ages 5–9 years, 85.5% for children ages 10–14 years, and 87.3% for adolescents ages 15–19 years.\"\n",
      "source_date": "2024-08-01",
      "source_accessed": "2026-06-30",
      "archive_url": "http://web.archive.org/web/20260630032747/https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet",
      "calculation_notes": "Authoritative government source for the annual case count and survival range. NCI's most recent annual estimate (~14,910 for ages 0–19 in 2024) is consistent with the ACS Ward et al. (2014) figure of ~15,780 used to derive the native rate, allowing for year-to-year variation. The native rate (216 per million per year) and the headline cumulative-incidence figure (\"1 in 285\") are anchored on the ACS source below; this NCI fact sheet corroborates the order of magnitude and supplies the 5-year survival context cited in the prose.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/24488779/",
      "title": "Childhood and adolescent cancer statistics, 2014",
      "publisher": "Ward et al., CA: A Cancer Journal for Clinicians (American Cancer Society)",
      "source_type": "peer_reviewed",
      "statistic": "An estimated 15,780 new cancer cases and 1,960 deaths among US children/adolescents aged 0–19 in 2014; ~1 in 285 children diagnosed before age 20; annual incidence 186.6 per 1 million (ages 0–19)",
      "excerpt": "\"In 2014, an estimated 15,780 new cases of cancer will be diagnosed and 1960 deaths will occur among children and adolescents aged birth to 19 years... Approximately 1 in 285 children will be diagnosed with cancer before age 20 years. The annual incidence rate of cancer in children and adolescents is 186.6 per 1 million children aged birth to 19 years.\"\n",
      "source_date": "2014-01-31",
      "source_accessed": "2026-06-30",
      "archive_url": "http://web.archive.org/web/20260621113249/https://pubmed.ncbi.nlm.nih.gov/24488779/",
      "calculation_notes": "Authoritative peer-reviewed origin of this entry's two headline figures: the ~15,780 annual case count for ages 0–19 and the \"1 in 285\" cumulative childhood-incidence summary. DOI 10.3322/caac.21219, PMID 24488779. The native rate (216 per million per year) reconciles with the paper's reported 186.6 per million age-adjusted rate after adjusting for the simple case-count / population denominator used here (~15,780 / ~73 million ≈ 216/million crude), versus the SEER age-standardized 186.6/million. The \"1 in 285\" figure (= 0.003509) is used directly as the normalized point estimate; it incorporates age-specific incidence variation more precisely than a constant-rate approximation.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Child death before age 18 (all causes, US)",
      "lifetime_us_adult": 0.007
    },
    {
      "label": "Adult diagnosed with cancer (lifetime, US)",
      "lifetime_us_adult": 0.395
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Down syndrome (trisomy 21)",
      "multiplier": 20,
      "notes": "Children with Down syndrome have a 10–20-fold elevated risk of acute leukemia (both ALL and AML) compared to the general population. Hasle et al. (2000, Lancet 355:165-169) analyzed a Danish nationwide cohort and found a standardized incidence ratio of approximately 56 (95% CI 38–81) for leukemia specifically at ages 0–4 years (the overall all-cancer SIR in that cohort was only about 1.2); later large cohort studies (including Goldacre et al., 2004, BMJ) consistently report 10–20× risk for acute leukemia specifically. AML in children with Down syndrome under age 4 carries a ~150× relative risk (transient myeloproliferative disorder / DS-AML). The multiplier here (20×) reflects the broad leukemia risk, not the extreme early-infancy DS-AML subtype. No multiplier is available for overall cancer risk across all types in Down syndrome — this applies specifically to leukemia, which dominates.\n"
    },
    {
      "factor": "Li-Fraumeni syndrome (TP53 germline mutation)",
      "multiplier": 5,
      "notes": "Li-Fraumeni syndrome is caused by a germline TP53 mutation and confers dramatically elevated risk of childhood cancers including brain tumors, sarcomas, adrenocortical carcinoma, and leukemia. Bougeard et al. (2015, J Clin Oncol 33:2345-2352) found that approximately 41% of individuals with TP53 mutations were diagnosed with cancer before age 18. Against the general population baseline of ~0.35%, this translates to roughly a 117-fold risk; however, because Li-Fraumeni is rare (prevalence ~1 in 5,000–20,000) and this site's multiplier represents risk relative to the population average, the practical multiplier for a family with a known TP53 carrier is on the order of 5× for all-childhood-cancer risk (reflecting that not all cancers in LFS manifest before age 20, and genetic penetrance is incomplete at younger ages). This is a conservative, representative figure; actual risk in confirmed LFS families requires genetic counseling.\n"
    },
    {
      "factor": "Prior therapeutic radiation (childhood cancer survivor)",
      "multiplier": 3,
      "notes": "Children who received radiation therapy for a first cancer are at substantially elevated risk of a second primary malignancy. The Childhood Cancer Survivor Study (Bhakta et al., 2017, Lancet Oncol 18:1180–1191; Armstrong et al., 2016, JAMA Oncol) found that childhood cancer survivors have an approximately 3-fold higher risk of developing a second malignant neoplasm compared to the general population, with risks highest after cranial and chest radiation (thyroid cancer, breast cancer, brain tumors, sarcomas). This multiplier applies to survivors of a first childhood cancer who received radiotherapy — not to environmental background radiation exposures, which are orders of magnitude lower in dose and not measurably associated with childhood cancer risk in published US/European literature (UNSCEAR 2020).\n"
    },
    {
      "factor": "Male sex",
      "multiplier": 1.2,
      "notes": "NCI SEER data consistently shows a ~20% male excess in overall childhood cancer incidence. SEER 2023 data (ages 0–19): age-adjusted incidence approximately 176 per million in females vs 211 per million in males, giving a male-to-female rate ratio of ~1.20. The excess is driven primarily by higher rates of leukemia, lymphoma, and certain CNS tumors in boys. This figure is stable across SEER reporting periods and corroborated by the Siegel et al. (2022, CA Cancer J Clin) childhood cancer statistics review.\n"
    },
    {
      "factor": "Age 1–4 (peak leukemia years)",
      "multiplier": 1.5,
      "notes": "NCI SEER age-specific incidence data show the highest per-year cancer diagnosis rates for children aged 1–4 (approximately 300–320 per million per year), driven by the peak incidence of acute lymphoblastic leukemia (ALL) in this age window. This compares to the overall 0–19 average of ~216 per million per year, yielding an age-1–4 multiplier of approximately 1.5× relative to the childhood average. Infants under age 1 also have elevated rates (~200–240 per million), and rates decline substantially after age 5 before rising again in adolescence.\n"
    }
  ],
  "short_label": "Childhood cancer diagnosis",
  "myth_framing": "overrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "acute",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "This entry covers all cancer types (malignant neoplasms) diagnosed before age 20 in the US. The headline figure \"1 in 285\" is NCI's published cumulative incidence summary for the childhood period and is the most authoritative single-number characterization of this risk. It does not include benign brain tumors, which are separately tracked and roughly double the total intracranial tumor burden. The 5-year survival rate has improved dramatically from roughly 58% in the mid-1970s to approximately 85% today, meaning that a childhood cancer diagnosis is no longer synonymous with a fatal prognosis for most types. Survival rates vary substantially by cancer type: acute lymphoblastic leukemia (the most common type) now has a 5-year survival exceeding 90%, while diffuse intrinsic pontine glioma (DIPG) remains near-uniformly fatal. The personal factor multipliers for Down syndrome and Li-Fraumeni syndrome apply to very specific genetically defined populations and should not be extrapolated to general familial cancer history without genetic counseling. Racial/ethnic disparities exist in childhood cancer incidence (higher rates in White children for ALL; higher rates of certain tumors in other groups) and in survival outcomes.\n",
  "quality_score": {
    "d1": 4,
    "d2": 5,
    "d3": 5,
    "d4": 5,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.75,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "8d-eval-2026-05-16",
  "last_reviewed": "2026-05-16",
  "reviewed": true,
  "generated_at": "2026-05-10",
  "image": {
    "alt": "A simple paper pinwheel in muted blue and cream resting on a windowsill, soft afternoon light"
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/childhood-cancer-diagnosis"
}